Toyota BZ4X vs BMW M8

What's the difference?

Toyota finds itself in a very unusual position - playing catch-up.

Usually the Japanese brand dominates any market segment it is in - or at least has one of the more popular offerings. But when it comes to mid-size electric SUVs, Toyota finds its bZ4X trailing well behind several rivals including the BYD Sealion 7, Geely EX5, Kia EV5, Tesla Model Y and Zeekr 7X. 

There’s a very clear reason for this, too. Toyota was late to the party. The brand has taken a very slow approach to the electric vehicle (EV) market, launching its first battery-powered model, the bZ4X SUV, in early 2024.

Up until the start of 2026 and a price drop that coincided with surging petrol prices and a spike in EV demand, the bZ4X was something of a bit-player in the EV market. But with sales up more than 300 per cent in 2026 the time seems perfect to expand, with the bZ4X Touring reaching dealerships.

So is this the right SUV at the right time? Or is it too little too late?

The right lane on Aussie freeways is occasionally referred to as the ‘fast lane’, which is laughable because the highest legal speed in the entire country is 130km/h (81mph). And that’s only on a few stretches in the Top End. Other than that, 110km/h (68mph) is all you’re getting.

Sure, a 'buck thirty' isn’t hanging around, but the subject of this review is a 460kW (625hp) four-door missile, capable of accelerating from 0-100 km/h in 3.2 seconds, and on to a maximum velocity somewhat in excess of our legal limit. 

Fact is, the BMW M8 Competition Gran Coupe is born and bred in Germany, where the autobahn’s left lane is serious territory, with open speed sections, and the car itself the only thing holding you back. In this case, to no less than 305km/h (190mph)!

Which begs the question, isn’t steering this machine onto an Aussie highway like cracking a walnut with a twin-turbo, V8-powered sledgehammer?

Well, yes, But by that logic a whole bunch of high-end, ultra high-performance cars would instantly become surplus to requirements here. Yet they continue to sell, in healthy numbers.  

So, there’s got to be more to it. Time to investigate.